News and reporting on cell-free DNA testing.
The agency issued a new draft decision memo, outlining various criteria it intends to apply when determining coverage for current and future blood-based CRC screening tests.
The partners will integrate CCPM's research biobank with personalized genomic information to develop and commercialize the saliva-based tests.
The unbiased method minimizes tearing of cells and inserts circulating tumor cells and leukocytes into a custom cell culture medium for later downstream analysis.
Natera said that the expanded coverage by Centene will add 24 million people for whom the Panorama noninvasive prenatal test will be covered.
Natera claims that several Genosity products infringe its US Patent No. 10,732,220, titled "Methods for Simultaneous Amplification of Target Loci."
